
Beren Therapeutics wins FDA approval for Lembaz (adrabetadex) targeting cholesterol transport in Niemann-Pick disease type C | Gif: fallontonight on Giphy
All the top Biotech & Pharma news in one daily newsletter.
Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣
✅ The Good News ✅
THE GOOD
Approvals & Labels
Beren Therapeutics wins FDA approval for Lembaz (adrabetadex) targeting cholesterol transport in Niemann-Pick disease type C
Small molecule, neurological, cyclodextrin, Niemann-Pick disease type C, cholesterol transport, rare disease - Read more
GSK's Nelkarmi (neladalkib) wins FDA accelerated approval for ALK-positive non-small cell lung cancer
Small molecule, cancer, tyrosine kinase inhibitor, non-small cell lung cancer, ALK-positive, drug resistance - Read more
Almirall's Klisyri (tirbanibulin) receives positive CHMP opinion for label expansion in actinic keratosis following Ph3 results
Small molecule, cancer, topical therapy, actinic keratosis, squamous cell carcinoma, field cancerization - Read more
THE GOOD
Business Development & Partnerships
Vertex Pharmaceuticals, Genomics renew four-year discovery partnership worth up to $220M
Research collaboration, drug discovery, AI/ML, milestone payments, royalties - Read more
Pfizer, Starna Therapeutics partner on in vivo CAR T autoimmune therapies, $330M upfront, $2.6B total deal
Licensing deal, autoimmune, cell therapy, RNA/LNP technology, milestone payments, royalties - Read more
Noetik collaborates with Memorial Sloan Kettering Cancer Center to advance AI cancer biology world models
Research collaboration, oncology, AI/ML, drug discovery, data analytics - Read more
PRESENTED BY SCIENCE 2 SALES
Outbound and commercial intelligence built exclusively for selling into biopharma.

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.
Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.
✅ More Good News ✅
THE GOOD
Clinical Trials
Biogen's (diranersen) shows 38% slowing of clinical decline at Ph2 Week 96 in Alzheimer's disease
Antisense oligonucleotide, neurological, Alzheimer's disease, tau protein, gene therapy - Read more
Lexeo Therapeutics reports positive Ph1/2 data for LX2020 targeting plakophilin-2 arrhythmogenic cardiomyopathy
Gene therapy, cardiovascular, arrhythmogenic cardiomyopathy, PKP2, ventricular tachycardia - Read more
Bristol Myers Squibb' Cobenfy (xanomeline/trospium chloride) shows Ph3 efficacy in Alzheimer's disease psychosis, but safety concerns remain
Small molecule, neurological, muscarinic antipsychotic, Alzheimer's disease, psychosis, xanomeline-trospium - Read more
THE GOOD
Fundraises
Onward Therapeutics raises $28M Series B to advance oncology clinical programmes
Oncology, bispecific antibody, NK cell therapy, small molecule, clinical-stage - Read more
Avalon BioVentures plans to raise $200M second fund, investing in biotech companies
Venture capital, biotech, therapeutics - Read more
Kernal Bio receives undisclosed IFLI investment to advance mRNA-encoded CAR-T candidate KR-402
mRNA therapy, CAR-T cell therapy, autoimmune, blood cancer, lipid nanoparticle, AI-driven - Read more
PRESENTED BY YOU?
Get the attention of 3000+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy
Do you offer a biotech/pharma-focused product or service?
Or looking to get investor/analyst interest on your budding start-up?
Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.
Just reply to this email* or message me on LinkedIn to learn more.
*If you’re reading this on the web version, email [email protected]
❌ The Bad News ❌
THE BAD
Clinical Trials
Cognito Therapeutics' Spectris AD Ph3 trial fails primary endpoint in Alzheimer's disease, mild subgroup shows signal
Non-invasive device, neurological, Alzheimer's disease, gamma sensory stimulation, APOE4, mild cognitive impairment - Read more
Priavoid's (PRI-002) all-D-peptide misses Ph2 primary endpoint in Alzheimer's disease trial
Small molecule, neurological, all-D-peptide, Alzheimer's disease, cognitive decline, p-tau181 - Read more
Merck & Co. discontinues (nemtabrutinib) BTK inhibitor program, including three Ph3 trials, over chronic lymphocytic leukemia/small lymphocytic lymphoma safety concerns
Small molecule, cancer, BTK inhibitor, chronic lymphocytic leukemia, hematology - Read more
THE BAD
Market Reports
Cassel Salpeter report warns U.S. tariffs, FDA disruptions disproportionately hurt small biotechs' fundraising
Biotech ecosystem, early-stage funding, regulatory, operational, financial - Read more
THE BAD
Regulatory
FDA proposes withdrawing Salerno Pharmaceuticals' FloLipid approval over repeated missing annual reports
Small molecule, cardiovascular, regulatory, operational - Read more
White House pulls FDA nominee Overton over vaccine, abortion drug, and vape policy concerns
FDA leadership, regulatory, operational - Read more
THE BAD
Strategic Plans
Kyntra Bio axes mid-stage CD46-targeting ADC program, saving $20M+ amid ongoing financial struggles
Antibody-drug conjugate, oncology, cost reduction, strategic - Read more
You’re all caught up on the latest Pharma & Biotech News!
TLDR Biotech wants to hear from you! 📣
Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝
If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️
And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis
Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here


